| Code | 7566C | ||||||||||
| MA number | 21/0126/18-S | ||||||||||
| Product Form: | cps dur 98x150 mg (fľ.HDPE) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | Vipharm S.A., Poland | ||||||||||
| Therapeutic Class: | 21 - ANTIEPILEPTICA, ANTICONVULSIVA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 11.04.2018 |
| PIL: |
PIL_Naxalgan cps dur_07.2024.pdf
|
| SPC: |
SPC_Naxalgan cps dur_07.2024.pdf
|
| Safety feature | Yes |
| Data update: | 27.08.2024 |
